TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03641248
Drug: Enteric coated Devil's Claw
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
Study: NCT03641248
Drug: Non-enteric coated Devil's Claw
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
Study: NCT06065059
Drug: TNG348
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquitin Specific Peptidase 1 (USP1) inhibitor
Study: NCT05122260
Drug: Q-Griffithsin
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal spray administered as a single dose
Study: NCT05764304
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one intra-articular injection every 4 months
Study: NCT04895293
Drug: RBM-007 Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution
Study: NCT05211804
Drug: Ophthalmic Drugs
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the same treatment as if not a part of the project
Study: NCT04480190
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusional 5-FU 225 mg/m2/d via Continuous IV infusion, to be given Days 1-5 and 8-12 during RT
Study: NCT05126264
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: morning and afternoon
Study: NCT05126264
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: morning, afternoon and night
Study: NCT04829799
Drug: Phenylephrine 1.0%/ Ketorolac 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
Study: NCT05848700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet
Study: NCT05946785
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
Study: NCT05783076
Drug: Stereotactic body radiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Details have been shown in arm descriptions.
Study: NCT05159895
Drug: [14C]-DZD9008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration
Study: NCT05068063
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
Study: NCT05788588
Drug: HR19006
Approvals — FDA: no, EMA: no, PMDA: no
Description: An emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume, administered via a central venous line over a time period of approximately 15 hours per day.
Study: NCT05788588
Drug: All-in-one parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial participants are prescribed TPN by the attending physician, which will be administered via a central venous line over a time period of approximately 15 hours per day. The formulation is an emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume (nitrogen content, heat and liquid quantity as equal as HR19006).
Study: NCT04656041
Drug: FOLFOX/ nal-IRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2) Oxaliplatin via IV, predetermined dosage per protocol~* 3) Leucovorin via IV, predetermined dosage per protocol~* 4) 5-Fluorouracil via IV, predetermined dosage per protocol
Study: NCT04942340
Drug: Atipamezole & Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
Study: NCT03843385
Drug: encapsulated faecal microbiota filtrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
Study: NCT03843385
Drug: encapsulated faecal microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
Study: NCT03843385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline encapsulated in hypromellose capsules and frozen.
Study: NCT06289920
Drug: BR3005
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone, Once a day
Study: NCT06289920
Drug: BR3005-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone, Once a day
Study: NCT06289920
Drug: BR3005-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone, Once a day
Study: NCT05055258
Drug: KVD824
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD824 300 mg Modified-Release Tablets
Study: NCT05055258
Drug: Placebo to KVD824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to KVD824 300 mg Modified-Release Tablets
Study: NCT06121141
Drug: Full strength lidocaine with epinephrine
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with epinephrine 1:100,000
Study: NCT06121141
Drug: Dilute lidocaine with epinephrine
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with epinephrine 1:100,000 diluted with normal saline (09.% NaCl) in a 1:4 ratio
Study: NCT06474507
Drug: Calculus bovis sativus (CBS)
Normalized name: Mycobacterium bovis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.
Study: NCT06201793
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline is a tetracycline antibiotic medication used to treat a number of bacterial infections such as pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis.
Study: NCT06669117
Drug: VERT-002
Normalized name: Wal-vert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of Administration: Intravenous
Study: NCT06399185
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
Study: NCT06607861
Drug: saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebulization of 4 mL 0.9% saline twice daily
Study: NCT05469243
Drug: Psychedelic
Approvals — FDA: no, EMA: no, PMDA: no
Description: retrospective survey of previous use
Study: NCT05363293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo formulation
Study: NCT06126952
Drug: Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 sprays per nostril of Placebo twice daily.
Study: NCT05256342
Drug: Etoricoxib 60 mg
Normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill daily for 8 weeks
Study: NCT06455410
Drug: GP
Normalized name: GPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine + cisplatin
Study: NCT06455410
Drug: concurrent chemoradiotherapy (CCRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: concurrent chemoradiotherapy (CCRT)
Study: NCT05327361
Drug: Liftactiv B3
Normalized name: VITAMIN B3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will apply a dime size amount of the serum to 1 side of the face.
Study: NCT04900337
Drug: AMOR 18 Powder & Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
Study: NCT04900337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
Study: NCT06508645
Drug: DWP14012 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)
Study: NCT06099418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
Study: NCT00002319
Drug: Doxorubicin hydrochloride (liposomal)
Normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05985278
Drug: [ Lu-177]-Catalase
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
Study: NCT06607926
Drug: Thymosin Alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 mg subcutaneous injection twice weekly over 12 weeks
Study: NCT06194955
Drug: GIP(1-42)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT06468527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 8 weeks. Oral administration.
Study: NCT05517213
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
Study: NCT04644796
Drug: saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
Study: NCT04782245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
Study: NCT06086444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
Study: NCT04709484
Drug: USG-guided steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
Study: NCT04709484
Drug: Palpation-guided steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
Study: NCT04796688
Drug: Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
Study: NCT04947631
Drug: DKF-313 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 48 weeks
Study: NCT04975958
Drug: AN2025
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT04975958
Drug: AN0025
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT05118984
Drug: Azithromycin capsule (Zithromax, Pfizer) (250 mg)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.
Study: NCT05118984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment that has no active properties
Study: NCT04924036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.
Study: NCT05180318
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT05632549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
Study: NCT05632549
Drug: L-Carnitine 500Mg Oral Tablet
Normalized name: L-Carnitine 500mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
Study: NCT05632549
Drug: Biotin Capsules
Normalized name: Biotin Capsules
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
Study: NCT05450887
Drug: Obeticholic Acid Tablets（OCA）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obeticholic Acid：Once a day (QD) by mouth (PO).
Study: NCT05450887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo：Once a day (QD) by mouth (PO).
Study: NCT05238012
Drug: Xuezhikang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
Study: NCT04914390
Drug: AT regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
Study: NCT05618730
Drug: Eye Drops, Lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
Study: NCT05300685
Drug: Standard Buccal Harvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Our institutions current anesthetic regimen. Comparison group
Study: NCT05300685
Drug: Basic buccal procedure + Long acting local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of long-acting local anesthetic to the wound bed following the oral graft harvest.
Study: NCT04766385
Drug: KHK7791
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT05445908
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
Study: NCT05445908
Drug: KL-A167
Approvals — FDA: no, EMA: no, PMDA: no
Description: KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
Study: NCT06127355
Drug: 500 mg of ursodeoxycholic acid (UDCA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 500 mg of ursodeoxycholic acid (UDCA) /day
Study: NCT06300723
Drug: BRL-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
Study: NCT05018806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT04798469
Drug: Testosterone Undecanoate 250 MG/ML
Normalized name: testosterone undecanoate 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
Study: NCT04798469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of placebo at baseline, weeks 4, and week 14.
Study: NCT05728151
Drug: Articaine and Epinephrine Only Product
Normalized name: Articaine and epinephrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
Study: NCT06149117
Drug: test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one capsule orally every cycle(T or R)
Study: NCT04844658
Drug: Strandard of care treatment
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strandard of care treatment for Covid-19 infection
Study: NCT05420467
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
Study: NCT04969965
Drug: aumolertinib
Normalized name: aumolertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
Study: NCT05420467
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
Study: NCT05420467
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, d1, q3w × 6 cycles
Study: NCT05602675
Drug: LY3871801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05602675
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT06465303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention is for each subject administered as three 30-minutes infusions of placebo
Study: NCT05074888
Drug: Prospekta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT05074888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT05502159
Drug: M-TAPA
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 40 ml (20 ml for each side) of %0,25 bupivacaine.
Study: NCT04972227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT05976503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04662073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match camostat administered orally four times daily
Study: NCT05804630
Drug: Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
Study: NCT06148311
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo will be given under the tongue on a thin dissolvable film.
Study: NCT05451719
Drug: Fruquintinib Plus Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W). Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
Study: NCT05451719
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
Study: NCT05986942
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
Study: NCT06052111
Drug: Group F (fentanyl group)
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation and was stopped 10 minutes before the end of surgery.
Study: NCT06052111
Drug: Group D (dexmedetomidine group)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of anesthesia followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
Study: NCT06453603
Drug: corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive pes anserinus corticosteroid injection
Study: NCT06214052
Drug: VH4524184
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4524184 will be administered.
Study: NCT06214052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06511739
Drug: SYHX1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHX1901 tablet